I came into Systems Biology from the Artificial Intelligence and Computational Linguistics background to inform computational methods with biological insight and help advance the state of probabilistic modeling and data analysis in biological medical research. My passion is understanding the root causes of aging and unlocking nature's mechanism for longevity and reversal of age-induced damage. Cancer, Alzheimer's, most other things we die of are the symptoms of underlying condition which must be cured - aging...
Kyle founded ETTA Biotechnology to create the most effective treatments targeting aging currently possible. The first therapies he designed have the potential to extend healthy human lifespan by 30+ years based on preclinical mouse studies and have seen safety, bioactivity, and hints of efficacy in human case studies. Kyle is a scientist and entrepreneur with >15 years of expertise in aging and biotechnology, with a special focus on delivery of small molecules, DNA, mRNA, and proteins to extend lifespan. Kyle researched synaptic vesicle...
Iosif M. Gershteyn is a serial entrepreneur with a track record of founding companies in the biologics (oncology) and medical device (pulmonology/telemedicine) industries. After completing his graduate studies in international economics and finance at Brandeis University in 2009, he started his career in asset management working on long-term qualitative investment strategies. Subsequently, he worked in corporate strategy (including mergers and acquisitions) and ultimately embarked on a career in technology entrepreneurship...
I’m Stephen Price, a data scientist, machine learning engineer, and computational biologist. I’ve worked 6+ years with a variety of biological, wearable sensor, and health data, and graduated from Carnegie Mellon School of Computer Science with a B.S. in Computational Biology. I’ve authored first-author publications in top research venues such as Bioinformatics and NeurIPS, and have worked across industry and academia at organizations such as Evidation Health, GlaxoSmithKline, and The Jackson Laboratory.
What is the most undervalued area for longevity progress we should pursue?
Data as a satellite product.
Where are we today? Where would we like to be?
Today we have data as a big bad entity that must be handled by specialists. We must first acknowledge the problem and be honest about how things really are. Then we can create data quality controls and standardization to make it easier to deal with large volumes of data.
What public and private actions have the biggest impact on those goals?
Government and NIST engaging with data quality improvement, and pilot projects creating low-cost federated longevity testing platforms.
What people, funding, resources, experiments would be required to test this hypothesis?
It may be possible to generate funding via the creation of a data token reward system.